The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Effects of Oral Ibandronate Administered Daily or Intermittently on Fracture Risk in Postmenopausal Osteoporosis
Open accessAbstract
Oral daily (2.5 mg) and intermittent ibandronate (between-dose interval of >2 months), delivering a similar cumulative exposure, were evaluated in 2946 osteoporotic women with prevalent vertebral fracture. Significant reduction in incident vertebral fracture risk by 62% and 50%, respectively, was shown after 3 years. This is the first study to prospectively show antifracture efficacy for the intermittent administration of a bisphosphonate. Introduction: Bisphosphonates are important therapeutics in postmenopausal osteoporosis. However, they are currently associated with stringent dosing instructions that may impair patient compliance and hence therapeutic efficacy. Less frequent, intermittent administration may help to overcome these deficiencies. This study assessed the efficacy and safety of oral ibandronate administered either daily or intermittently with a dose-free interval of >2 months. Materials and Methods: This randomized, double-blind, placebo-controlled, parallel-group study enrolled 2946 postmenopausal women with a BMD T score ≤ −2.0 at the lumbar spine in at least one vertebra (L1-L4) and one to four prevalent vertebral fractures (T4-L4). Patients received placebo or oral ibandronate administered either daily (2.5 mg) or intermittently (20 mg every other day for 12 doses every 3 months). Results and Conclusions: After 3 years, the rate of new vertebral fractures was significantly reduced in patients receiving oral daily (4.7%) and intermittent ibandronate (4.9%), relative to placebo (9.6%). Thus, daily and intermittent oral ibandronate significantly reduced the risk of new morphometric vertebral fractures by 62% (p = 0.0001) and 50% (p = 0.0006), respectively, versus placebo. Both treatment groups also produced a statistically significant relative risk reduction in clinical vertebral fractures (49% and 48% for daily and intermittent ibandronate, respectively). Significant and progressive increases in lumbar spine (6.5%, 5.7%, and 1.3% for daily ibandronate, intermittent ibandronate, and placebo, respectively, at 3 years) and hip BMD, normalization of bone turnover, and significantly less height loss than in the placebo group were also observed for both ibandronate regimens. The overall population was at low risk for osteoporotic fractures. Consequently, the incidence of nonvertebral fractures was similar between the ibandronate and placebo groups after 3 years (9.1%, 8.9%, and 8.2% in the daily, intermittent, and placebo groups, respectively; difference between arms not significant). However, findings from a posthoc analysis showed that the daily regimen reduces the risk of nonvertebral fractures (69%; p = 0.012) in a higher-risk subgroup (femoral neck BMD T score < −3.0). In addition, oral ibandronate was well tolerated. Oral ibandronate, whether administered daily or intermittently with an extended between-dose interval of >2 months, is highly effective in reducing the incidence of osteoporotic fractures in postmenopausal women. This is the first time that significant fracture efficacy has been prospectively shown with an intermittently administered bisphosphonate in the overall study population of a randomized, controlled clinical trial. Thus, oral ibandronate holds promise as an effective and convenient alternative to current bisphosphonate therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Ibandronate reduces the incidence of vertebral fractures by about 50 % over 3 years, but reduction in risk of nonvertebral fracture with ibandronate has not been documented [50].”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [50]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This is true for fracture patients with BMD in both the low bone mass and osteoporosis range [49–58].”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [50]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“There are abundant data that patients with spine and hip fractures will have reduced fracture risk if treated with pharmacologic therapy.”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [50]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Ibandronate reduces the incidence of vertebral fractures by about 50 % over 3 years, but reduction in risk of nonvertebral fracture with ibandronate has not been documented [50].”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [50]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Black, D. M., Cummings, S. R., Karpf, D. B., Cauley, J. A., Thompson, D. E., Nevitt, M. C., Bauer, D. C., Genant, H. K., Haskell, W. L., Marcus, R., et al. (1996) · The Lancet · doi:10.1016/s0140-6736(96)07088-2 · Cited by 3,846
Liberman, U. A., Weiss, S. R., Bröll, J., Minne, H. W., Quan, H., Bell, N. H., Rodriguez-Portales, J. A., Downs, R. W., Dequeker, J., Favus, M. J., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511303332201 · Cited by 2,276
Self-citationEffect of Risedronate on the Risk of Hip Fracture in Elderly Women
McClung, M. R., Geusens, P., Miller, P. D., Zippel, H., Bensen, W. G., Roux, C., Adami, S., Fogelman, I., Diamond, T., Eastell, R., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200102013440503 · Cited by 1,918
Self-citationReginster, J.-Y., Minne, H. W., Sorensen, O. H., Hooper, M., Roux, C., Brandi, M. L., Lund, B., Ethgen, D., Pack, S., Roumagnac, I., et al. (2000) · Osteoporosis International · doi:10.1007/s001980050010 · Cited by 1,580
Fracture Risk Reduction with Alendronate in Women with Osteoporosis: The Fracture Intervention Trial
Black, D. M., Thompson, D. E., Bauer, D. C., Ensrud, K., Musliner, T., Hochberg, M. C., Nevitt, M. C., Suryawanshi, S., & Cummings, S. R. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.11.6953 · Cited by 982
Noninvasive assessment of bone mineral and structure: State of the art
Genant, H. K., Engelke, K., Fuerst, T. P., Glüer, C., Grampp, S., Harris, S. T., Jergas, M. D., Lang, T., Lü, Y., Majumdar, S., et al. (1996) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650110602 · Cited by 948
Intermittent Cyclical Etidronate Treatment of Postmenopausal Osteoporosis
Watts, N. B., Harris, S. T., Genant, H. K., Wasnich, R. D., Miller, P. D., Jackson, R. D., Licata, A. A., Ross, P. D., Woodson, G. C., Yanover, M., et al. (1990) · New England Journal of Medicine · doi:10.1056/nejm199007123230201 · Cited by 947
Self-citationStorm, T., Thamsborg, G., Steiniche, T., Genant, H. K., & Sørensen, O. H. (1990) · New England Journal of Medicine · doi:10.1056/nejm199005033221803 · Cited by 926
Research works printed but not linked: 4
- Melton, 1991, Long-term fracture risk prediction with bone mineral measurements made at various skeletal sites, J Bone Miner Res, 6, S136
- Kendler, 2002, Patient preference of once weekly or daily administration of alendronate (Fosamax) for osteoporosis: a randomized cross-over study, Osteoporos Int, 13, S32
- Palmisano, 2002, Preference study of alendronate 70 mg once weekly and alendronate 10 mg once daily in postmenopausal women with osteoporosis, Osteoporos Int, 13, S36
- Kiel, 1995, Assessing vertebral fractures. National Osteoporosis Foundation Working Group on Vertebral Fractures, J Bone Miner Res, 10, 518
Cited by
Sorted by citations
Items 301–400 of 999
Effects of antiresorptive treatment on nonvertebral fracture outcomes
Mackey, D. C., Black, D. M., Bauer, D. C., McCloskey, E. V., Eastell, R., Mesenbrink, P. G., Thompson, J. R., & Cummings, S. R. (2011) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.446 · Cited by 46
Renal safety of intravenous bisphosphonates in the treatment of osteoporosis
Lewiecki, E. M., & Miller, P. D. (2007) · Expert Opinion on Drug Safety · doi:10.1517/14740338.6.6.663 · Cited by 46
Bone Mineral Density Change in Systemic Lupus Erythematosus: A 5-year Followup Study
ZHU, T. Y., Griffith, J. F., Au, S.-K., Tang, X.-L., Kwok, A. W. L., Leung, P., Li, E. K., & Tam, L. (2014) · The Journal of Rheumatology · doi:10.3899/jrheum.131190 · Cited by 46
Imai, K. (2013) · Clinical Interventions in Aging · doi:10.2147/cia.s37199 · Cited by 47
Stakkestad, J. A., Lakatos, P. L., Lorenc, R. S., Sedarati, F., Neate, C., & Reginster, J. (2008) · Clinical Rheumatology · doi:10.1007/s10067-007-0824-6 · Cited by 46
Self-citationBisphosphonates pharmacology and use in the treatment of osteoporosis
Diab, D. L., Watts, N. B., & Miller, P. D. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-813073-5.00074-5 · Cited by 46
Miller, P. D. (2005) · Clinical Therapeutics · doi:10.1016/j.clinthera.2005.04.005 · Cited by 46
Bobba, R. S., BEATTIE, K. A., Parkinson, B., Kumbhare, D. A., & Adachi, J. D. (2006) · Drug Safety · doi:10.2165/00002018-200629120-00005 · Cited by 47
Progress in osteoporosis and fracture prevention: focus on postmenopausal women
Saag, K. G., & Geusens, P. (2009) · Arthritis Research & Therapy · doi:10.1186/ar2815 · Cited by 47
Use of bisphosphonates in the management of postmenopausal osteoporosis
Papapoulos, S. E. (2010) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2010.05767.x · Cited by 45
Adachi, J. D., Lynch, N., Middelhoven, H., Hunjan, M., & Cowell, W. (2007) · BMC Musculoskeletal Disorders · doi:10.1186/1471-2474-8-97 · Cited by 45
Papapoulos, S. E., & Schimmer, R. C. (2007) · Postgraduate Medical Journal · doi:10.1136/ard.2006.064931 · Cited by 46
Self-citationOsteoporosis Diagnosis and Medical Treatment
Warriner, A. H., & Saag, K. G. (2013) · Orthopedic Clinics of North America · doi:10.1016/j.ocl.2013.01.005 · Cited by 44
Effects of ONO-5334, a novel orally-active inhibitor of cathepsin K, on bone metabolism
Ochi, Y., Yamada, H., Mori, H., Nakanishi, Y., Nishikawa, S., Kayasuga, R., Kawada, N., Kunishige, A., Hashimoto, Y., Tanaka, M., et al. (2011) · Bone · doi:10.1016/j.bone.2011.09.041 · Cited by 44
Gronholz, M. J. (2008) · PubMed · Cited by 44
Time to onset of efficacy in fracture reduction with current anti-osteoporosis treatments
Inderjeeth, C. A., Chan, K., Kwan, K., & Lai, M. M. Y. (2012) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-012-0349-1 · Cited by 45
Induction of osteogenesis by bone-targeted Notch activation
Xu, C., Dinh, V. V., Kruse, K., Jeong, H.-W., Watson, E. C., Adams, S., Berkenfeld, F., Stehling, M., Rasouli, S. J., Fan, R., et al. (2022) · eLife · doi:10.7554/elife.60183 · Cited by 42
Update on the treatment of post-menopausal osteoporosis
Cole, Z. A., Dennison, E. M., & Cooper, C. C. (2008) · British Medical Bulletin · doi:10.1093/bmb/ldn017 · Cited by 43
Siddique, M. M., Frost, M. L., Blake, G. M., Moore, A. E. B., Al-Beyatti, Y., Marsden, P. K., Schleyer, P. J., & Fogelman, I. (2011) · Journal of Nuclear Medicine · doi:10.2967/jnumed.111.093195 · Cited by 43
Patient preference in the management of postmenopausal osteoporosis with bisphosphonates
Reginster, J., & Rabenda, V. (2006) · Clinical Interventions in Aging · doi:10.2147/ciia.2006.1.4.415 · Cited by 42
New Approaches to the Treatment of Osteoporosis
Silva, B. C. C., & Bilezikian, J. P. (2010) · Annual Review of Medicine · doi:10.1146/annurev-med-061709-145401 · Cited by 42
Vescini, F., Attanasio, R., Balestrieri, A., Bandeira, F. A. F., Bonadonna, S., Camozzi, V., Cassibba, S., Cesareo, R., Chiodini, I., Francucci, C. M., et al. (2016) · Journal of Endocrinological Investigation · doi:10.1007/s40618-016-0434-8 · Cited by 43
Importance of Recent Fracture as Predictor of Imminent Fracture Risk
Schnell, A., Curtis, J. R., & Saag, K. G. (2018) · Current Osteoporosis Reports · doi:10.1007/s11914-018-0487-z · Cited by 42
Medical treatment of osteoporosis
Palacios, S. (2021) · Climacteric · doi:10.1080/13697137.2021.1951697 · Cited by 47
Could Strontium Ranelate Have a Synergistic Role in the Treatment of Osteoporosis?
Blake, G. M., Compston, J. E., & Fogelman, I. (2009) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.090601 · Cited by 38
A Comprehensive Approach to Fragility Fractures
Rebolledo, B. J., Unnanuntana, A., & Lane, J. M. (2011) · Journal of Orthopaedic Trauma · doi:10.1097/bot.0b013e3181f9b389 · Cited by 41
Menatetrenone (Vitamin K2) and Bone Quality in the Treatment of Postmenopausal Osteoporosis
Iwamoto, J., Takeda, T., & Satō, Y. (2006) · Nutrition Reviews · doi:10.1111/j.1753-4887.2006.tb00184.x · Cited by 42
The Correction of BMD Measurements for Bone Strontium Content
Blake, G. M., & Fogelman, I. (2007) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2007.03.102 · Cited by 41
Ip, T., Cheung, S.-K. W., Cheung, S.-K. W., Cheung, T.-C., Choi, T.-C., Chow, S.-L. E., Kan, S.-Y. A., Kung, W. C. A., Lee, K.-K., Leung, K. L. F., et al. (2013) · PubMed · Cited by 41
Calcitonin: A useful old friend.
Srinivasan, A., Wong, F. Y. K., & Karponis, D. (2020) · PubMed Central · Cited by 39
Rud, B., Hilden, J., Hyldstrup, L., & Hróbjartsson, A. (2008) · Osteoporosis International · doi:10.1007/s00198-008-0713-0 · Cited by 40
Therapeutic Treatments for Osteoporosis—Which Combination of Pills Is the Best among the Bad?
Tonk, C. H., Shoushrah, S. H., Babczyk, P., Khaldi-Hansen, B. E., Schulze, M., Herten, M., & Tobiasch, E. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031393 · Cited by 44
A Review of Strontium Ranelate and Its Effect on DXA Scans
Blake, G. M., Lewiecki, E. M., Kendler, D. L., & Fogelman, I. (2007) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2007.01.002 · Cited by 40
Reginster, J., Felsenberg, D., Cooper, C. C., Stakkestad, J. A., Miller, P. D., Kendler, D. L., Adami, S., McClung, M. R., Bolognese, M. A., Civitelli, R., et al. (2005) · Osteoporosis International · doi:10.1007/s00198-005-1957-6 · Cited by 40
Self-citationLateral Femoral Bowing and the Location of Atypical Femoral Fractures
Yoo, H.-S., Cho, Y.-H., Park, Y.-B., & Ha, S.-S. (2017) · Hip & Pelvis · doi:10.5371/hp.2017.29.2.127 · Cited by 39
Bone anabolic versus bone anticatabolic treatment of postmenopausal osteoporosis
Lyritis, G. P., Γεωργούλας, Θ., & Zafeiris, C. (2010) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2010.05666.x · Cited by 42
Miller, P. D., & Derman, R. J. (2010) · Osteoporosis International · doi:10.1007/s00198-010-1208-3 · Cited by 39
Zhou, J. M., Liao, Y., Xie, H., Liao, Y., Zeng, Y., Li, N., Sun, G., Wu, Q., & Zhou, G. (2016) · Bioelectromagnetics · doi:10.1002/bem.22012 · Cited by 39
Recent Developments in Bisphosphonate Therapy
Silverman, S. L., & Maricic, M. J. (2007) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2006.12.003 · Cited by 38
Narongroeknawin, P., Patkar, N. M., Shakoory, B., Jain, A., Curtis, J. R., Delzell, E., Lander, P., Lopez‐Ben, R., Pitt, M. J., Safford, M. M., et al. (2011) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2011.09.001 · Cited by 38
Sclerostin monoclonal antibody therapy with AMG 785: a potential treatment for osteoporosis
Lewiecki, E. M. (2010) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2011.540565 · Cited by 38
Assessment of non-vertebral fracture risk in postmenopausal women
Roux, C., Briot, K., Horlait, S., Varbanov, A. R., Watts, N. B., & Boonen, S. (2007) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2006.064071 · Cited by 36
Lewiecki, E. M., Babbitt, A. M., Piziak, V. K., Ozturk, Z. E., & Bone, H. G. (2008) · Clinical Therapeutics · doi:10.1016/j.clinthera.2008.04.009 · Cited by 37
Imaging of Site Specific Bone Turnover in Osteoporosis Using Positron Emission Tomography
Blake, G. M., Siddique, M. M., Frost, M. L., Moore, A. E. B., & Fogelman, I. (2014) · Current Osteoporosis Reports · doi:10.1007/s11914-014-0231-2 · Cited by 37
Ibandronate does not increase risk of atrial fibrillation in analysis of pivotal clinical trials
Lewiecki, E. M., Cooper, C. C., Thompson, E., Hartl, F., Mehta, D., & Papapoulos, S. E. (2010) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2010.02335.x · Cited by 36
Osteoporosis in Postmenopausal Women
Sanders, S., & Geraci, S. A. (2013) · Southern Medical Journal · doi:10.1097/smj.0b013e3182a0df8b · Cited by 37
Safety of drugs used in the treatment of osteoporosis
McGreevy, C., & Williams, D. J. (2011) · Therapeutic Advances in Drug Safety · doi:10.1177/2042098611411012 · Cited by 37
Feng, Z., Zeng, S., Wang, Y., Zheng, Z., & Chen, Z. (2013) · PLoS ONE · doi:10.1371/journal.pone.0080890 · Cited by 36
Clinical role of bisphosphonate therapy
Fogelman, I., & Hampson (2012) · International Journal of Women s Health · doi:10.2147/ijwh.s24783 · Cited by 37
2011 Up-Date of the Consensus Statement of the Spanish Society of Rheumatology on Osteoporosis
Pérez-Edo, L., Ruiz, A. A., Vilaseca, D. R., García-Vadillo, A., Gay, N. G., Peris, P., Eslava, A. T., Audera, C. B., Aresté, J. F., Rodríguez, L. M. A., et al. (2011) · Reumatología Clínica (English Edition) · doi:10.1016/j.reumae.2011.05.007 · Cited by 36
Seeto, A. H., Abrahamsen, B., Ebeling, P. R., & Rodríguez, A. J. (2020) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.4157 · Cited by 36
A 55-Year-Old Woman With Osteopenia
Cummings, S. R. (2006) · JAMA · doi:10.1001/jama.296.21.2601 · Cited by 36
Effects of ibandronate on bone quality: Preclinical studies
Bauss, F., & Dempster, D. W. (2006) · Bone · doi:10.1016/j.bone.2006.08.002 · Cited by 36
Bisphosphonate Therapy and Atypical Fractures
Saleh, A., Hegde, V. V., Potty, A. G. R., & Lane, J. M. (2013) · Orthopedic Clinics of North America · doi:10.1016/j.ocl.2013.01.001 · Cited by 35
Predictors of new and severe vertebral fractures: results from the HORIZON Pivotal Fracture Trial
Wustrack, R. L., Seeman, E., Bucci-Rechtweg, C. M., Burch, S., Palermo, L., & Black, D. M. (2011) · Osteoporosis International · doi:10.1007/s00198-011-1664-4 · Cited by 35
Absolute risk reduction in osteoporosis: assessing treatment efficacy by number needed to treat
Ringe, J. D., & Doherty, J. G. (2009) · Rheumatology International · doi:10.1007/s00296-009-1311-y · Cited by 35
Lozano, J. V., Pallarés‐Carratalá, V., Cea‐Calvo, L., Llisterri, J. L., Fernández, C., Martí-Canales, J. C., Aznar, J., Gil-Guillén, V. F., Redón, J., & on behalf of the investigators of the PReV-ICTUS Study (2008) · Current Medical Research and Opinion · doi:10.1185/030079908x273372 · Cited by 35
Updated Recommendations for the Diagnosis and Management of Osteoporosis: A Local Perspective
Raef, H., Al-Bugami, M., Balhareth, S. S., Moawad, M. A., El-Shaker, M., Hussain, A. N., Al-Shaikh, A., & Al-Badawi, I. A. (2011) · Annals of Saudi Medicine · doi:10.4103/0256-4947.77502 · Cited by 36
Calcium Citrate and Vitamin D in the Treatment of Osteoporosis
Gómez, J. M., Blanch‐Rubió, J., Díaz Curiel, M., & Díez‐Pérez, A. (2011) · Clinical Drug Investigation · doi:10.1007/bf03256927 · Cited by 36
Fogelman, I., & Blake, G. M. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67867-1 · Cited by 35
Sebba, A. I., Emkey, R. D., Kohles, J. D., & Sambrook, P. N. (2008) · Bone · doi:10.1016/j.bone.2008.10.052 · Cited by 35
Developments in the pharmacotherapeutic management of osteoporosis
Close, P., Neuprez, A., & Reginster, J. (2006) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.7.12.1603 · Cited by 35
Teriparatide and the risk of nonvertebral fractures in women with postmenopausal osteoporosis
Krege, J. H., & Wan, X. (2011) · Bone · doi:10.1016/j.bone.2011.10.018 · Cited by 34
Risks and benefits of long-term bisphosphonate therapy
Schmidt, G. A., Horner, K. E., McDanel, D. L., Ross, M. B., & Moores, K. G. (2010) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp090506 · Cited by 35
Giusti, A. (2014) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-014-0584-8 · Cited by 34
Site specific measurements of bone formation using [18F] sodium fluoride PET/CT
Blake, G. M., Puri, T., Siddique, M. M., Frost, M. L., Moore, A. E. B., & Fogelman, I. (2018) · Quantitative Imaging in Medicine and Surgery · doi:10.21037/qims.2018.01.02 · Cited by 35
Anabolic and antiresorptive actions of locally delivered bisphosphonates for bone repair
Qayoom, I., Raina, D. B., Širka, A., Tarasevičius, Š., Tägil, M., Kumar, A., & Lidgren, L. (2018) · Bone and Joint Research · doi:10.1302/2046-3758.710.bjr-2018-0015.r2 · Cited by 34
Primer: the fallacy of subgroup analysis
Guillemin, F. (2007) · Nature Clinical Practice Rheumatology · doi:10.1038/ncprheum0528 · Cited by 34
Hd, N., Em, H., Chou, R., Dana, T., Fu, R., & Bougatsos, C. (2010) · Europe PMC (PubMed Central) · Cited by 34
Closing the gap in osteoporosis management: the critical role of primary care in bone health
Singer, A. J., Sharma, A. K., Deignan, C., & Borgermans, L. A. D. (2023) · Current Medical Research and Opinion · doi:10.1080/03007995.2022.2141483 · Cited by 36
Recent Advances in Osteoporosis Therapeutics
Sølling, A. S., Langdahl, B. L., & Cosman, F. (2025) · Annual Review of Medicine · doi:10.1146/annurev-med-050124-040555 · Cited by 42
Safety concerns with the long-term management of osteoporosis
Reginster, J., Pelousse, F., & Bruyère, O. (2013) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2013.793669 · Cited by 33
McGowan, B., Casey, M. C., Silke, C., Whelan, B., & Bennett, K. (2012) · Osteoporosis International · doi:10.1007/s00198-012-2032-8 · Cited by 33
Osteoporosis, densidad mineral ósea y complejo CKD-MBD (II): implicaciones terapéuticas
Bover, J., Ureña, P., Láiz, A. M., Torregrosa, J., Rodríguez-García, M., Castro-Alonso, C., Górriz, J. L., Benito, S., López‐Báez, V., Cora, M. J. L., et al. (2019) · Nefrología · doi:10.1016/j.nefro.2018.10.009 · Cited by 37
Postmenopausal osteoporosis. What have we learned since the introduction of bisphosphonates?
Chaiamnuay, S., & Saag, K. G. (2006) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-006-9008-y · Cited by 32
Ellis, A. G., Reginster, J., Luo, X., Cappelleri, J. C., Chines, A. A., Sutradhar, S., & Jansen, J. P. (2014) · Value in Health · doi:10.1016/j.jval.2014.01.008 · Cited by 32
SEIOMM Working Group, Guañabens, N., Moro-Álvarez, M. J., Casado, E., Blanch‐Rubió, J., Gómez‐Alonso, C., Diaz‐Guerra, G. M., del Pino‐Montes, J., Valero, C., Peris, P., et al. (2019) · Endocrine · doi:10.1007/s12020-019-01919-8 · Cited by 33
Cosman, F. (2009) · Endocrine Practice · doi:10.4158/ep08306.orr1 · Cited by 32
Analytical methods for the quantification of ibandronate in body fluids and bone
Endele, R., Loew, H., & Bauss, F. (2005) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2005.03.020 · Cited by 33
New therapeutic agents for the treatment of bone diseases
Lipton, A. (2005) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.5.6.817 · Cited by 34
Orozco, C., & Maalouf, N. M. (2012) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2012.09.001 · Cited by 33
Bisphosphonate Drug Holiday: Choosing Appropriate Candidates
Ro, C., & Cooper, O. B. (2013) · Current Osteoporosis Reports · doi:10.1007/s11914-012-0129-9 · Cited by 32
Osteoporosis in the Women's Health Initiative: Another Treatment Gap?
Sattari, M., Cauley, J. A., GARVAN, C. W., Johnson, K., LaMonte, M. J., Li, W., Limacher, M. C., Manini, T. M., Sarto, G. E., Sullivan, S. D., et al. (2017) · The American Journal of Medicine · doi:10.1016/j.amjmed.2017.02.042 · Cited by 34
Javaid, M. K. (2021) · Aging Clinical and Experimental Research · doi:10.1007/s40520-021-01844-9 · Cited by 35
Strategies for transdermal drug delivery against bone disorders: A preclinical and clinical update
Sharma, G., Alle, M., Chakraborty, C., & Kim, J. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.06.035 · Cited by 32
Frost, M. L., Siddique, M., Blake, G. M., Moore, A. E. B., Marsden, P. K., Schleyer, P. J., Eastell, R., & Fogelman, I. (2011) · Osteoporosis International · doi:10.1007/s00198-011-1805-9 · Cited by 32
Recker, R. R., Ste‐Marie, L., Langdahl, B. L., Czerwinski, E. J., Bonvoisin, B., Masanauskaite, D., Rowell, L., & Felsenberg, D. (2009) · Bone · doi:10.1016/j.bone.2009.11.004 · Cited by 34
Self-citationPrevention of osteoporosis-related fractures among postmenopausal women and older men
Rahmani, P., & Morin, S. N. (2009) · Canadian Medical Association Journal · doi:10.1503/cmaj.080709 · Cited by 32
Blake, G. M., Siddique, M. M., Frost, M. L., Moore, A. E. B., & Fogelman, I. (2011) · Bone · doi:10.1016/j.bone.2011.05.031 · Cited by 32
Keen, R. W., Jódar, E., Iolascon, G., Kruse, H. ‐., Varbanov, A. R., Mann, B., & Gold, D. T. (2006) · Current Medical Research and Opinion · doi:10.1185/030079906x154079 · Cited by 31
Longitudinal change in clinical fracture incidence after initiation of bisphosphonates
Abelson, A. G., Ringe, J. D., Gold, D. T., Lange, J. L., & Thomas, T. (2009) · Osteoporosis International · doi:10.1007/s00198-009-1046-3 · Cited by 33
Emkey, R. D., Delmas, P. D., Bolognese, M. A., Borges, J. L. C., Cosman, F., Ragi-Eis, S., Recknor, C. P., Zerbini, C. A. F., Neate, C., Sedarati, F., et al. (2009) · Clinical Therapeutics · doi:10.1016/j.clinthera.2009.04.018 · Cited by 33
Self-citationTreatment of postmenopausal osteoporosis
Reginster, J. (2005) · BMJ · doi:10.1136/bmj.330.7496.859 · Cited by 32
Osteonecrosis de los maxilares: Documento de consenso
Henríquez, M. S., Romero, M. G. D. T., Jv, B. S., Díaz Curiel, M., Díez Pérez, A., Jódar Gimeno, E., Junquera Gutiérrez, L., Del Pino Montes, J., Barrero, M. V., Científico, M. D. C., et al. (2009) · DOAJ (DOAJ: Directory of Open Access Journals) · Cited by 30
Akehurst, R. L., Brereton, N. J., Ariely, R., Lusa, T., Groot, M. D., Foss, P., & Boonen, S. (2011) · Journal of Medical Economics · doi:10.3111/13696998.2010.545563 · Cited by 31
Adoption of Once-monthly Oral Bisphosphonates and the Impact on Adherence
Briesacher, B. A., Andrade, S. E., Harrold, L. R., Fouayzi, H., & Yood, R. A. (2010) · The American Journal of Medicine · doi:10.1016/j.amjmed.2009.05.017 · Cited by 31
Silverman, S. L., Gold, D. T., & Cramer, J. A. (2007) · Southern Medical Journal · doi:10.1097/smj.0b013e31815a9685 · Cited by 31
Chandran, M. (2022) · Archives of Endocrinology and Metabolism · doi:10.20945/2359-3997000000564 · Cited by 34
Vilaça, T., Schini, M., Lui, L., Ewing, S. K., Thompson, A. R., Vittinghoff, E., Bauer, D. C., Eastell, R., Black, D. M., & Bouxsein, M. (2024) · Journal of Bone and Mineral Research · doi:10.1093/jbmr/zjae126 · Cited by 35
Wang, G., Sui, L., Gai, P. Y., Li, G., Qi, X., & Jiang, X. (2017) · Bone and Joint Research · doi:10.1302/2046-3758.67.bjr-2016-0292.r1 · Cited by 30
Metadata
- Authors
- Chesnut, C. H., Skag, A., Christiansen, C., Recker, R., Stakkestad, J. A., Hoiseth, A., Felsenberg, D., Huss, H., Gilbride, J., Schimmer, R. C., Delmas, P. D., & (BONE), F. T. O. I. O. V. F. T. I. N. A. A. E.
- Affiliations
- University of Washington (US)
- Center for Clinical Trials, Bergen, Norway
- Center for Clinical & Basic Research (DK)
- Creighton University (US)
- CECOR AS, Haugesund, Norway
- Oslo Department, Sentrum Røntgen Institut AS, Oslo, Norway
- Universitatsklinikum Benjamin Franklin, Berlin, Germany
- Leverkusen, Germany
- Roche (United Kingdom) (GB)
- F. Hoffmann-La Roche AG (CH)
- Lyon 1 Université (FR)
- Corresponding author
- Chesnut, Charles H
- Venue
- Journal of Bone and Mineral Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2004-08-01
- Volume
- 19
- Issue
- 8
- Pages
- 1241-1249
- ISSN
- 0884-0431 (ISSN-L)
- 1523-4681
- OpenAlex
- W2099054178
- Cited by
- 1,229
- References
- 42
- Citations by year
- 2026: 14 · 2025: 38 · 2024: 20 · 2023: 42 · 2022: 31 · 2021: 37 · 2020: 35 · 2019: 32 · 2018: 32 · 2017: 31 · 2016: 43 · 2015: 45 · 2014: 45 · 2013: 63 · 2012: 62
- FWCI
- 85.94
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- Locations
- Journal of Bone and Mineral Research (publishedVersion)
- PubMed (publishedVersion)
- Funders
- F. Hoffmann-La Roche
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
- Keywords
- ibandronate, intermittent dosing, bisphosphonates, postmenopausal osteoporosis, vertebral fractures, fracture risk reduction, bone mineral density, bone turnover, height loss, drug safety, medication adherence, lumbar spine, hip bone density, antifracture efficacy, treatment discontinuation, adverse events
- MeSH terms
- Ibandronic Acid, Aged, Body Height, Bone and Bones, Diphosphonates, Double-Blind Method, Female, Femur, Humans, Lumbar Vertebrae, Middle Aged, Pelvic Bones, Prospective Studies, Risk Factors, Bone Density, Osteoporosis, Postmenopausal, Spinal Fractures, Treatment Outcome, Patient Selection, Fractures, Bone
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
